Cover Image

Validating Alzheimer's disease micro RNAs using next-generation sequencing

Abstract Introduction Molecular biomarkers for Alzheimer's disease (AD) can support detection and improved care for patients, but novel candidates require verification. We previously reported a 12-micro RNA (miRNA) blood-based signature using next-generation sequencing (NGS) of 54 AD cases and...

Full description

Saved in:
Bibliographic Details
Main Authors: Keller, Andreas (Author) , Backes, Christina (Author) , Haas, Jan (Author) , Leidinger, Petra (Author) , Maetzler, Walter (Author) , Deuschle, Christian (Author) , Berg, Daniela (Author) , Ruschil, Christoph (Author) , Galata, Valentina (Author) , Ruprecht, Klemens (Author) , Stähler, Cord (Author) , Würstle, Maximilian (Author) , Sickert, Daniel (Author) , Gogol, Manfred (Author) , Meder, Benjamin (Author) , Meese, Eckart (Author)
Format: Article (Journal)
Language:English
Published: [2016]
In: Alzheimer's and dementia
Year: 2016, Volume: 12, Issue: 5, Pages: 565-576
ISSN:1552-5279
DOI:10.1016/j.jalz.2015.12.012
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jalz.2015.12.012
Verlag, lizenzpflichtig, Volltext: https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1016/j.jalz.2015.12.012
Get full text
Author Notes:Andreas Keller, Christina Backes, Jan Haas, Petra Leidinger, Walter Maetzler, Christian Deuschle, Daniela Berg, Christoph Ruschil, Valentina Galata, Klemens Ruprecht, Cord Stähler, Maximilian Würstle, Daniel Sickert, Manfred Gogol, Benjamin Meder, Eckart Meese
Description
Summary:Abstract Introduction Molecular biomarkers for Alzheimer's disease (AD) can support detection and improved care for patients, but novel candidates require verification. We previously reported a 12-micro RNA (miRNA) blood-based signature using next-generation sequencing (NGS) of 54 AD cases and 22 controls. Methods We performed validation of 49 AD cases and 55 controls using NGS and also included 20 mild cognitive impairment and 90 multiple sclerosis samples to identify nonspecific markers. Thus, 103 AD cases, 77 unaffected controls, and 110 diseased controls were sequenced. Although the initial cohort came predominantly from the United States, the validation samples were collected in Germany. Results Five hundred eighty miRNAs were detected in the blood. In the initial cohort, we observed 203, in the validation cohort, 146 dysregulated miRNAs at a significance level of 0.05. With 68 miRNAs, the overlap was significant (P = .0003). Likewise, the area under the receiver operator characteristic curve values of the miRNAs correlated (correlation of 0.93; 95% confidence interval 0.89?0.96; P <10?16). Discussion MiRNAs have the potential to support AD diagnosis and patient care.
Item Description:Gesehen am 11.05.2020
Physical Description:Online Resource
ISSN:1552-5279
DOI:10.1016/j.jalz.2015.12.012

Similar Items